BMO Capital Downgrades Covidien Ltd (COV) to Market Perform

Go back to BMO Capital Downgrades Covidien Ltd (COV) to Market Perform

Barclays Downgrades Covidien Ltd (COV) to Equalweight

June 18, 2014 7:13 AM EDT

Barclays downgraded Covidien Ltd (NYSE: COV) from Overweight to Equalweight.

For an analyst ratings summary and ratings history on Covidien Ltd click here. For more ratings news on Covidien Ltd click here.

Shares of Covidien Ltd closed at $88.12 yesterday.

... More

Needham & Company Comments on Sector Implications Amid Medtronic (MDT)/Covidien (COV) Megadeal

June 16, 2014 7:30 AM EDT

Needham & Company analyst Mike Matson comments on the sector implications amid Medtronic's (NYSE: MDT) $42.9 billion deal to acquire Covidien (NYSE: COV).

The analyst said while the media is likely to focus on the tax inversion angle, which is certainly playing a role, they... More

William Blair Downgrades Covidien Ltd (COV) to Market Perform

June 16, 2014 7:18 AM EDT

William Blair downgraded Covidien Ltd (NYSE: COV) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Covidien Ltd click here. For more ratings news on Covidien Ltd click here.

Shares of Covidien Ltd closed at $72.02 yesterday.

... More

UPDATE: JPMorgan Upgrades Medtronic, Inc. (MDT) to Overweight

June 16, 2014 6:59 AM EDT

(Updated - June 16, 2014 11:35 AM EDT)

JPMorgan upgraded Medtronic, Inc. (NYSE: MDT) from Neutral to Overweight with a price target of $78.00 (from $64.00). The upgrade follows Medtronics agreement to acquire Covidien (NYSE: COV).

Analyst Michael... More

Medtronic (MDT) to Acquire Covidien (COV) in $42.9B Deal

June 16, 2014 6:12 AM EDT

Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, and Covidien plc (NYSE: COV), a global healthcare technology and medical supplies provider, today announced that they have entered into a definitive agreement under which Medtronic has agreed to acquire Covidien in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic`s closing stock price of $60.70 per share on June 13, 2014.

Once the transaction is completed, Medtronic will have significantly advanced its position as the world`s premier... More

Medtronic (MDT) in Advanced Talks to Acquire Covidien (COV) - WSJ

June 14, 2014 12:20 PM EDT

Medtronic (NYSE: MDT) is in advanced talks to acquire Covidien (NYSE: COV) for more than $40 billion, the Wall Street Journal reported Saturday citing people familiar with the matter. The deal price suggests a premium of at... More